Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daclizumab Has Winning Efficacy In MS, But Safety Questions Linger

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Top-line results from a Phase IIb trial of Biogen Idec Inc./Abbott Laboratories Inc.'s daclizumab in relapsing-remitting multiple sclerosis are impressive, but data from an ongoing Phase III trial may clear up lingering questions about the drug's safety profile.

You may also be interested in...



Energized Biogen Idec On Track For Two Filings In 2012

Biogen hopes to submit marketing applications in the U.S. and Europe for both MS therapy BG-12 and its therapies for hemophilia A and B in 2012, with launches possible in early and mid-2013.

Disappointing BRAVO Data Raise Doubts About Laquinimod’s Chances

Teva Pharmaceuticals Co. Ltd. is facing investor doubts about regulatory prospects for its oral multiple sclerosis drug laquinimod after the drug missed the primary endpoint in a second Phase III trial, called BRAVO.

Disappointing BRAVO Data Raise Doubts About Laquinimod’s Chances

Teva Pharmaceuticals Co. Ltd. is facing investor doubts about regulatory prospects for its oral multiple sclerosis drug laquinimod after the drug missed the primary endpoint in a second Phase III trial, called BRAVO.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS004804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel